Peer-reviewedCC BY-NCJournal of Brown hospital medicine
Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
Related
- Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review
- Gene‐Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium‐Glucose Cotransporter‐2 Inhibitors
- Early Initiation of Sodium-Glucose Cotransporter 2 Inhibitors in Acute Decompensated Heart Failure: Efficacy, Safety, and Implementation in Stabilized Patients
- Sodium–Glucose Cotransporter-2 Inhibitors in World Health Organization Group 1 Pulmonary Arterial Hypertension: A REVEAL Lite 2–Matched Cohort With Time-Varying Exposure Analysis
- Sodium–Glucose Cotransporter-2 Inhibitors in World Health Organization Group 1 Pulmonary Arterial Hypertension: A REVEAL Lite 2–Matched Cohort With Time-Varying Exposure Analysis
BibTeX
@article{anon2026sodiumglucose,
title = {{Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects}},
journal = {Journal of Brown hospital medicine},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13664655},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
PY - 2026
DA - 2026/10/16
JO - Journal of Brown hospital medicine
UR - https://europepmc.org/article/PMC/PMC13664655
SN - 2994-5593
ER -